<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

Announcing MLM Medical Labs' Acquisition of MD Biosciences, Inc.

Posted by MD Biosciences on Oct 26, 2020 11:06:56 AM

We are happy to announce that we have merged with MLM Medical Labs ("MLM"), a specialized laboratory dedicated to clinical trials headquartered in Germany. With our strong reputation for scientific expertise in immunology and immunological biomarkers and distinguished approach to customer care, our team is looking forward to joining the MLM family, and providing a comprehensive menu of preclinical and clinical services to an extended client base. 

 

MD Biosciences' life science research products manufacturing and distribution businesses in Switzerland and the US, and MD Biosciences' neurology business focused on preclinical and translational research in neurology in Israel and the US, are not part of this transaction. 

 

The addition of MD Biosciences follows the acquisition of CirQuest Labs in Memphis, TN earlier this summer, further expanding MLM's geographic reach. The integration of the three organizations will occur in the coming few months to align the operations and quality systems, offering customers access to MLM services in both the United States and Europe. With a stronger and larger global team, "we will have the scale and capacity to support all stages of product development", says Stephan Voswinkel, Managing Director of MLM.

 

"Joining the growing MLM family is the next step in the evolution of MD Biosciences, Inc., providing an expanded geographic reach in immunology and biomarker testing services. This opens the opportunity to serve MD Biosciences' growing roster of customers with their needs in Europe, the US and with the combined strength of MLM and CirQuest", commented Eddie Moradian, CEO of MD Biosciences.

 

MLM global services will include: 

  • expertise in pre-clinical and clinical research across various therapeutic areas including inflammation, autoimmune, metabolism and oncology
  • full-service histopathology lab including immunohistochemistry and digital image analysis 
  • specialized biomarker testing
  • clinical chemistry
  • analyses of drug compounds
  • molecular diagnostics 

official press release

We look forward to continuing to serve you with an expanded menu of capabilities, supporting all stages of research. To learn more about MLM Medical Labs, visit the website here. 

 

Read More

Topics: Preclinical Discovery, precision medicine, translational, Immuno-Oncology, drug development, preclinical research, Biotechnology, Histology, Tissue Processing

LPS-induced Lung Injury and Fibrosis Models for COVID-19 Therapeutic Developments

Posted by MD Biosciences on Sep 29, 2020 3:51:28 PM

Most severe COVID-19 patients develop pneumonia and hyper-inflammation, likely
related to a macrophage activation syndrome commonly named “cytokine storm”.
The overproduction of early response pro-inflammatory cytokines (tumor necrosis
factor [TNF], IL-6, and IL-1β) results in an increased risk of vascular hyper-permeability,
multi-organ failure, and eventually death, when the high cytokine concentrations are unabated over time.
 
The pathophysiology of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2)-induced acute respiratory distress syndrome (ARDS) has similarities to that
of severe community-acquired pneumonia caused by other viruses or bacteria. LPS
induced ARDS is widely used to study host-response patterns in the pulmonary
compartment.
 
The LPS lung inflammation model is an acute lung inflammation model where researchers can observe the pulmonary response following exposure to bacteria. Following induction by the oral aspiration of LPS, leukocytes are recruited into the lung cavity and parenchyma. Therefore, using this model, it is possible to measure and characterize the cellular profile of recruited leukocytes to the lung airways as well as the levels of pro-inflammatory cytokines.
 
Linked to the inflammatory response, lung fibrosis emerges as a secondary event
related to the progression of the pathology. Understanding the link between the
hyper-inflammation phase and fibrosis will give rise to new therapeutic targets
especially beneficial in the most severe cases of COVID-19. Our bleomycin-induced
fibrosis model accurately mimics this process. With one single dose of bleomycin, there is the onset of an acute inflammatory response, followed by fibrogenic changes, resulting in deposition of matrix and distortion of lung structure. The bleomycin model of pulmonary fibrosis is very helpful to illustrate pathobiology in vivo and to identify new targets for medication. It is an extremely beneficial tool to assess efficacy of potential compounds in general as proof of principle. 
 

 
How can MD Biosciences be value-added to your inflammation programs? Contact our scientific team to start a conversation. 
Read More

Topics: preclinical research, COVID-19

Commercialization of Novel Assays for COVID-19 Therapeutics

Posted by MD Biosciences on Sep 15, 2020 11:39:11 AM

Our team is excited to announce that we have signed an agreement in partnership with IncellDx, Inc., a global leader in single-cell diagnostics, to evaluate therapeutic biomarkers in COVID-19 and other cytokine storm conditions.

 

With our esoteric immune-based testing, we will validate and offer lab testing in the United States and European Union to measure levels of COVID/cytokine storm-related therapeutics. "Such cytokines are significantly elevated in patients with COVID-19, and usually remain abnormal in recovering patients, but still are suffering from symptoms. These patients are referred to as 'long-haulers' (PR News Centre, 2020)". 

 

To read the full article published by PR News Centre, follow the link below and learn more. 

Learn More

How can MD Biosciences support your clinical programs? Please contact our team with any questions, we are happy to speak with you! 

Email Us

+1 (651) 641-1770

 

Read More

Topics: Inflammation, Biomarkers, Personalized medicine, CLIA, Cytokines, clinical research, clinical diagnostics, COVID-19

Announcing MD Biosciences Neuro, LLC in Cambridge, MA

Posted by MD Biosciences on Sep 3, 2020 10:15:00 AM

We are happy to announce that we have established MD Biosciences Neuro, LLC. in Cambridge, Massachusetts to expand our work and collaborations in the United States. Our team, led by Chief Scientific Officer, Sigal Meilin, is looking forward to developing close partnerships with you and continuing to advance the field of neurology and pain research.
Learn MoreWith a multifaceted approach to assessment of neurological diseases, specializations include pain-related work, neurodegenerative diseases including Parkinson's, neuro-inflammatory diseases such as Multiple Sclerosis (MS), and capabilities in stroke and cerebral ischemia. Preclinical models are complimented by in house histology, biomarker analysis and electrophysiology capabilities. Finally, our unique porcine models share a high degree of similarity to humans, thus offering greater clinical efficacy that serve to augment and accelerate your program towards their next objectives and milestones.


Please contact us with any questions about our services, capabilities, and customizable study design options.

Request Study Proposal

Read More

Topics: Pain, news, Neuro/CNS, Preclinical Discovery, neuropathic pain, Life Science, translational, assays, drug development, preclinical research, disease models, Biotechnology, Behavioral Research, porcine model, Neuroscience

Announcing MD Biosciences Bioproducts, LLC in Oakdale, MN

Posted by MD Biosciences on Sep 2, 2020 12:15:08 PM

We are happy to announce that we have established MD Biosciences Bioproducts, LLC. in Oakdale, Minnesota to expand our work and collaborations worldwide. Our team is dedicated to the development, manufacturing and distribution of life science research products suited for inflammatory and autoimmune diseases, neurology, oncology, pain, and metabolism.

View Products

It is our goal to collaborate with pharmaceutical, biotech, academic and government communities to provide you with the tools needed to optimize your research process enabling you to reach your objectives faster. We offer antibodies, reagents and assays for use in various therapeutic areas of research.

 

                                       Please contact us with any questions about our products and capabilities. 

Contact Us

Read More

Topics: news, Research Products, Preclinical Discovery, Life Science, assays, drug development, clinical research, Biotechnology

Why Pigs? MD Biosciences Published in Göttingen Minipigs Magazine

Posted by MD Biosciences on Mar 17, 2020 2:06:14 PM

MD Biosciences lab was featured with Ellegaard offering an exclusive expertise in pain studies. The article discusses our work to develop and validate models in adult pigs, specifically for chronic and acute pain.

 

View Publication Here

 

When do we recommend to work with minipigs?

MD Biosciences pigs studies include domestic pigs and Göttingen minipigs.

The main advantage of the minipig is that it gains weight much slower than the domestic pig. This could be significant when:

  • The study requires working with adult animals
  • When we run models with chronic diseases ( ≥3 months)
  • Tox and ADME studies are run in Göttingen minipigs, which is significant for standardization

 

Pig models at MD Biosciences: 

Post-Operative Pain

Modified Post-Operative Pain

Neuropathic Pain

Wound Healing

 


Ready to learn how your research can accelerate with pig studies? Contact us today! +1 (651) 641-1770 or info-us@mdbiosciences.com 

 

Read More

Topics: Pain, post-operative pain, neuropathic pain, translational, Wound Healing, translational research, Behavioral Research, porcine model, Neuroscience

Novel Data For MBP-Induced EAE Presented at NeuroImmunology Conference

Posted by MD Biosciences on Mar 10, 2020 11:20:22 AM

Due to the clinical and pathological similarities of experimental autoimmune encephalomyelitis (EAE) and Multiple Sclerosis (MS), EAE  is a model for the study of human demyelinating disease. Both EAE and MS are characterized by a relapsing-remitting disease course with subsequent progressive disability. EAE is characterized by chronic inflammatory demyelination of the central nervous system (CNS) and involves autoimmune CD4+ Th1 cells. These cells develop in the peripheral lymphoid organ and travel to the CNS causing an immune response. The development of T cells is controlled largely by the expression of various cytokines, as well as cellular adhesion molecules.

 

This past month in Paris, our scientists presented at the NeuroImmunology Conference, where they shared novel data in the Myelin Basic Protein (MBP) Induced model used to mimic Multiple Sclerosis (MS). This model is a powerful tool for studying disease pathogenesis as well as potential therapeutic interventions. Below find our poster data. 

 

When conducting MS research,  administration of one dose of MPB in a Lewis rat leads to a single relapse that is characterized by hind paw paralysis. This can be characterized histologically, by infiltration of mononuclear cells to the cervical spinal cord and formation of foci. This model is self-limiting and does not show demyelination.

 

 

Screenshot 2020-03-04 13.16.39

 

 

Other MS-EAE Models at MD Biosciences: 

PLP

MBP

MOG


 

Interested to learn about customizable models for neurodegenerative disease research? Contact us today! 

Contact Us

Read More

Topics: Neuro/CNS, preclinical research, translational research, disease models, Neuroscience, NeuroImmunology

MD Biosciences Runs NeuroScientific Study: Publishes Positive Results in Fight Against Alzheimer's

Posted by MD Biosciences on Aug 5, 2019 10:46:44 AM

View Publication Here

Our team of neuroscience specialists ran a preclinical study with NeuroScientific Biopharmaceuticals in hopes of progressing towards a human trial later in the year for Alzheimer's. Using lead drug candidate EmtinB known to stimulate the reformation of the neuronal network and restore function of damaged nerve cells, the nerve cells were successfully able to communicate again in this study. In fact, EmtinB was able to stimulate regeneration of nerve cells by more than 300% compared to the control. This is significant in affecting synapse loss, a key contributor of cognitive impairment. Together, we are paving the way for successful therapeutic treatment options for Alzheimer's. Learn about our neurodegenerative animal models, behavioral assessments and other neuroscience research services here! 

Read More

Topics: CRO/outsourcing, Neuro/CNS, preclinical research, Behavioral Research, Neuroscience, Nerve Injury, Alzheimer's

MD Biosciences Launches Neuroscience Services Website: featuring neuropathic pain, neurodegenerative disease models and electrophysiology capabilities

Posted by MD Biosciences on Jun 7, 2019 10:20:59 AM

Now live: a website dedicated to MD Biosciences' cutting-edge neurological and CNS research services offered through our Neuroscience Research Laboratories. Our facilities are fitted with state-of-the-art equipment and technologies for preclinical and translational studies, featuring clinically-relevant read outs and endpoints. Specialties include studies of neuropathic, acute and chronic pain and neurodegenerative/neuroinflammatory diseases. Unique pig translational models and electrophysiology capabilities compliment rodent capabilities and accelerate your program towards their next objectives and milestones. Contact our team today! 651-641-1770 or info@mdbiosciences.com 
Visit Neuroscience Services Website

Read More

Topics: Pain, news, Neuro/CNS, in vivo pain models, post-operative pain, Biomarkers, neuropathic pain, Neuropathy, assays, Batch Release Testing, preclinical research, translational research, Electrophysiology, Behavioral Research, porcine model, Neuroscience, Nerve Injury

PNT Pig Model: Highly valuable data for translational pain research

Posted by MD Biosciences on Apr 4, 2019 11:00:00 AM

Despite massive investment in research for treatment options, there are not many effective and safe therapeutics for human chronic neuropathic pain (NP) afflictions. Options are limited due to the lack of translatable animal models, especially large animals who have similar physical and metabolic features to humans (Rice et al., 2008, Henze and Urban, 2010, Swindle et al., 2012). MD Biosciences, Inc. has developed a modified unilateral sciatic nerve PNT model in pigs that produces sustained NP behaviors consistent with those observed in human pain patients. The pig PNT model provides highly valuable data for translational pain research. 

                          Read more in our scientists' latest publication here


MD Biosciences translational models can be enhanced with behavioral analysis capabilities, electrophysiology recordings, histology/IHC services and more. Contact us today for more information: info-us@mdbiosciences.com or (651) 641-1770.

Contact Us

Read More

Topics: Pain, neuropathic pain, translational research, Behavioral Research, porcine model, Histology